Insight Molecular Diagnostics Inc. (IMDX): Formerly Oncocyte Corporation, the Company Has Rebranded and Relocated Its Headquarters.

OncoCyte has rebranded to Insight Molecular Diagnostics and relocated its headquarters to Nashville, Tennessee. The company's stock will trade under the new symbol 'IMDX' on the Nasdaq Stock Market starting June 18, 2025. The rebranding reflects the company's expanded strategic direction and diversified product portfolio, including a focus on transplant medicine.

On June 17, 2025, Insight Molecular Diagnostics Inc. (formerly Oncocyte Corporation) announced a significant rebranding and relocation of its principal executive office. The company, which will now trade under the new stock symbol "IMDX" on the Nasdaq Stock Market, has changed its name to Insight Molecular Diagnostics Inc. and moved its headquarters from Irvine, California, to Nashville, Tennessee. This move coincides with the company's expanded strategic direction and diversified product portfolio, including a focus on transplant medicine [1].

The new name, Insight Molecular Diagnostics Inc., more accurately reflects the company's mission to deliver precision biomarker-based testing for both transplant and oncology care. The company's Chief Financial Officer, Andrea James, stated, "We believe that iMDx is just getting started in its value-creation journey, and that these changes reflect our renewed priorities and focus" [1].

The relocation to Nashville, Tennessee, is strategically aligned with the company's operations and proximity to core infrastructure and industry talent. Nashville is home to the company's CLIA-certified lab, which launched as "Insight Molecular Labs" in 2013 and maintains that name today. The company will also maintain its laboratory and research and development center in Göttingen, Germany [1].

Insight Molecular Diagnostics Inc. will be exhibiting at the European Society for Organ Transplantation (ESOT) Congress in London from June 29 to July 2, 2025. The company will showcase its GraftAssureIQ™ pilot site program, a research-use-only (RUO) initiative designed to support transplant centers engaged in cutting-edge research [1].

As part of the rebranding initiative, the company is retiring the VitaGraft name and unifying its transplant diagnostics under the GraftAssure™ brand. The updated nomenclature will better align with each product's regulatory classification and intended use. For example, the VitaGraft Kidney lab-developed test (LDT) will be rebranded as GraftAssureCore, while the RUO test kit will be rebranded as GraftAssureIQ [1].

The new iMDx logo features DNA banding patterns on the "i" and a centered "MD," reflecting the company's healthcare provider-centric philosophy. The new identity captures the company's mission to provide deep insights through science and empower better decisions in transplant care, oncology, and beyond [1].

References:
[1] https://www.biospace.com/press-releases/oncocyte-changes-name-to-insight-molecular-diagnostics-inc-imdx-moves-headquarters-to-nashville